Three Things To Watch Out For Roche This Year
Roche (NASDAQ:RHHBY) is a global leader when it comes to cancer drugs. If you have invested in the company’s stock, its cancer therapeutics business is something you have to monitor closely. Here we present three key aspects to look out for this year, as far as Roche’s business and growth prospects are concerned. There is a common theme binding each of these, and that is Roche’s oncology stalwarts Avastin, Herceptin and Rituxan. Needless to say, the company’s priority is to have a long term plan to replace these drugs as they go off patent and biosimilars hit the market.
Relevant Articles
Have more questions about Roche? See the links below.
- Roche’s Stock May Have Been Down, But The Company’s Business Has Strong Outlook
- What Drove 15% Growth in Roche’s Earnings Between 2011-2014 Even Though Other Big Pharma Companies Suffered A Decline?
- Why Is Market Assigning Low Earnings Multiple To Roche Despite Its Biotech Focus?
- Can Roche Grow Its Earnings By 15% In The Next 3 Years?
- With Biosimilars Getting Approval In Europe, Does Roche’s 2016 EPS Face A Meaningful Risk?
- How Can Roche Get 25% Boost In Revenues In 5 Years?
- Can Emerging Biosimilar Competition Cause > 10% Downside To Roche’s Valuation?
- Here Is Why We Are Bullish On Roche
Notes:
1) The purpose of these analyses is to help readers focus on a few important things. We hope such lean communication sparks thinking, and encourages readers to comment and ask questions on the comment section, or email content@trefis.com
2) Figures mentioned are approximate values to help our readers remember the key concepts more intuitively. For precise figures, please refer to our complete analysis for Roche
See More at Trefis | View Interactive Institutional Research (Powered by Trefis)